Kemin Pharma B.v.b.a.

Kemin Industries, Inc.

Universiteit Gent

Kemin Pharma Europe B.v.b.a.

.kemin Foods, L.c.

Resilux

Benedikt J Sas

Eric Peys

Jan Vandenkerckhove

Johan Van Hemel

Johan Van Der Eycken

Bart Ruttens

Petra Blom

Clifford A Adams

Steven Van Hoof

Jan Balzarini

Richard Ducatelle

Tom Anthierens

Annemieke Madder

Filip Van Immerseel

Filip Du Prez

Freddy Haesebrouck

Frank Pasmans

Assia Ouchchen

Ingrid Somers

Venessa Eeckhaut

Sarah De Saeger

Sam Verbrugghe

Frank Devlieghere

Lynda Beladjal

Johan Mertens

Eddy Van Beek

Eric De Clercq

Vincent Ornelis

Andreja Rajkovic

The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use in the detection, isolation and detoxification of such ionophoric compounds. The present invention further provides the use of such synthetic receptors in human and veterinary medicine, such as in the diagnosis, prevention and/or treatment of disorders caused by such ionophoric compounds. Finally, the invention provides methods of preparing such synthetic receptors for ionophoric compounds.

Synthetic receptors for ionophoric compounds

The present application relates to methods for producing materials having viable micro-organisms incorporated therein. More particularly, the materials are produced under high temperature and/or high pressure conditions, and the micro-organisms are incorporated in the material before or during these conditions. Also provided are micro-organisms that remain viable under these conditions and have different applications, depending on the nature of the material.

Incorporation of thermo-resistant and/or pressure-resistant organisms in materials

The present invention relates to butyrate producing bacterial strains related to the speciesto be used in the prevention and/or treatment of intestinal health problems. The present invention therefore provides methods and compositions that overcome the problems associated with the currently used methods for administering butyric acid in the treatment of intestinal health problems in humans and/or animals.

Method for alleviating intestinal problems and novel bacterial strains therefor

The use of sesquiterpenes and, in particular sesquiterpene lactone endoperoxides, such as artemisinin and analogs thereof, for the treatment of hepatitis C virus infections. Artemisinin, analogs of artemsisnin and some crudeextracts were tested in vitro against DNA-viruses, retro-viruses and, (an important family of human and animal RNA pathogens). These compounds were also screened for anti-tumor activity. Strong activity of artemisinin was noticed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), we can conclude that endoperoxides in general and artemisinin more specifically have efficacy as treatments for hepatitis C viral infections.

Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus

Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors. The compounds are of the general formula: 

Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity

The synthesis and study of biological activity of a series of new molecules with potential antimicrobial activity are described. The molecules are bicyclic carbohydrates, based on furanose sugars. Their antimicrobial activity against viruses is demonstrated, next to cytostatic effects. Significantly, a high and selective activity against Cytomegalovirus was observed.

Furanose-type bicyclic carbohydrates with biological activity

A method for improving the performance of enzymes used in animal feeds by the use of surfactants. Lecithin and/or lysolecithin is added to an animal feed including an exogenous enzyme to boost the performance of the enzyme so that a desired level of performance can be maintained while reducing the amount of exogenous enzyme that must be included in the animal feed. Preferably, the surfactant includes lyso-forms of lecithin.

Method for improving the activity of enzymes

The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tumors, bacteria and fungi. Compound A1, a thiophenyl-containing bicyclic carbohydrate possessed significant activity against, a parasite that causes the lethal sleeping sickness. Compound A2 and Compound A3, bicyclic carbohydrates with halogen containing aryl groups, possessed significant activity against, a parasite that causes leishmaniasis. Bicyclic carbohydrates in general, and Compound A1, Compound A2 and Compound A3 more specifically, could be possible treatments for the sleeping sickness and leishmaniasis in the future.

Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites

We describe the use of bicyclic carbohydrates for the treatment of hepatitis C virus infections. Different bicyclic carbohydrates were tested in vitro against DNA-viruses, retro-viruses andsp., an important family of human and animal RNA pathogens. Significant activity was observed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), the bicyclic carbohydrates in general and the preferred bicyclic carbohydrates more specifically are expected to be a treatment for hepatitis C viral infections.

[object Object]

Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein Ris either -Bn or -Ph; Rand Rare either -alkyl, -aryl, -allyl, or &#x2014;H; Rand Rform a ring and are either &#x2014;CH(Ph)- or &#x2014;CH(aryl)- and X is either O, N or S.

Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae

Novel bicyclic carbohydrate compounds are effective for the prophylaxis and treatment of diseases caused by infections of the alphaherpesvirinae HSV-1 and HSV-2. The invention includes the compound wherein X, X, and Xare selected from the group consisting of O, N, and S; wherein Yand Yare selected from the group consisting of O, N, and S; and wherein Z is selected from the group consisting of F, Cl, and Br, as well as analogs, prodrugs and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions for the prophylaxis and treatment of diseases caused by infections of alphaherpesvirinae.

Bicyclic carbohydrates as antiviral bioactives for the treatment of infections caused by the alphaherpesvirinae HSV-1 and HSV-2

This invention relates to the in situ process for converting non-free-form xanthophylls to free xanthophylls in the biological material of the plant. The method, more particularly, relates to a method that would liberate xanthophylls by transesterification of acyl-xanthophylls in plant materials which is used as a natural food colorant.

Conversion of xanthophylls in plant material for use as a food colorant

Conversion of crude lecithin is performed by incubating the lecithin with a lipase-phospholipase mixture in a water/polyol environment. The incubation is carried out at about 40-50.degree. C. and a pH of about 7 to about 8 while stirring continuously. The reaction simultaneously produces lysolipid, lysophospholipid, monoglycerides, and diglycerides. The conversion rate of lecithin is more than 80% based on the ratio of LPC/PC (lysophosphatidylcholine/phosphatidylcholine). Calcium chloride can be added to the reaction mixture to capture released fatty acids.

Method for the conversion of lecithin into lysolecithin

This invention relates to the in sito process for converting non-free form xanthophylls to free xanthophylls in the biological material of the plant. The method, more particularly, relates to a method that would liberate xanthophylls by transesterification of acyl-xanthophylls in plant materials.

Growing community of inventors

Turnhout, Belgium

Benedikt J Sas